EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY-NC-ND 4.0

Time to Benefit of Surgery vs Targeted Medical Therapy for Patients With Primary Aldosteronism: A Meta-analysis

Sunil Samnani, Irena Cenzer, Gregory A Kline, Sei J Lee, Gregory L Hundemer, Caitlin McClurg, Janice L Pasieka iD, W John Boscardin, Paul E Ronksley, Alexander A Leung iD

The Journal of Clinical Endocrinology & Metabolism · 20.02.2024 · 109 (3) · e1280-e1289

DOI: 10.1210/clinem/dgad654 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 08.11.2023. Verfasst von Sunil Samnani und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB T2T 5C7, Canada. Hauptthemen laut MEDLINE: Diabetes Mellitus, Hypertension, Renal Insufficiency, Chronic, Hyperaldosteronism. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, CIHR, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Primary aldosteronism (PA) is one of the most common causes of secondary hypertension, but the comparative outcomes of targeted treatment remain unclear.

Objective

To compare the clinical outcomes in patients treated for primary aldosteronism over time.

Methods

Medline and EMBASE were searched. Original studies reporting the incidence of mortality, major adverse cardiovascular outcomes (MACE), progression to chronic kidney disease, or diabetes following adrenalectomy vs medical therapy were selected. Two reviewers independently abstracted data and assessed study quality. Standard meta-analyses were conducted using random-effects models to estimate relative differences. Time to benefit meta-analyses were conducted by fitting Weibull survival curves to estimate absolute risk differences and pooled using random-effects models.

Results

15 541 patients (16 studies) with PA were included. Surgery was consistently associated with an overall lower risk of death (hazard ratio [HR] 0.34, 95% CI 0.22-0.54) and MACE (HR 0.55, 95% CI 0.36-0.84) compared with medical therapy. Surgery was associated with a significantly lower risk of hospitalization for heart failure (HR 0.48 95% CI 0.34-0.70) and progression to chronic kidney disease (HR 0.62 95% CI 0.39-0.98), and nonsignificant reductions in myocardial infarction and stroke. In absolute terms, 200 patients would need to be treated with surgery instead of medical therapy to prevent 1 death after 12.3 (95% CI 3.1-48.7) months.

Conclusion

Surgery is associated with lower all-cause mortality and MACE than medical therapy for PA. For most patients, the long-term surgical benefits outweigh the short-term perioperative risks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes MellitusHypertensionRenal Insufficiency, ChronicHyperaldosteronismHumansTime

Stichwörter der Autor:innen

hyperaldosteronismmineralocorticoid receptor antagonistsurgerytime to treatment benefit

Autor:innen und Institutionen

  • Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB T2T 5C7, Canada.
  • Division of Geriatrics, Department of Medicine, University of California (SanFrancisco), San Francisco, CA 94121, USA.
  • Geriatrics, Palliative and Extended Care Service Line, SanFrancisco VA (Veterans Affairs) Health Care System, San Francisco, CA 94121, USA.
  • Department of Medicine (Division of Nephrology) and the Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON K1H 7W9, Canada.
  • Library and Cultural Resources, University of Calgary, Calgary, AB T2N 4N1, Canada.
  • Departments of Surgery and Oncology, University of Calgary, Calgary, AB T2N 2T9, Canada.

ORCID-Profile: Janice L Pasieka, Alexander A Leung

Förderung

  • NIA NIH HHS
  • CIHR
  • Canadian Institutes of Health Research
  • Heart and Stroke Foundation of Canada’s National New Investigator Award
  • Lorna Jocelyn Wood Chair in Kidney Research

Zitieren

APA

Samnani, S., Cenzer, I., Kline, G. A., Lee, S. J., Hundemer, G. L., McClurg, C., Pasieka, J. L., Boscardin, W. J., Ronksley, P. E., & Leung, A. A. (2024). Time to Benefit of Surgery vs Targeted Medical Therapy for Patients With Primary Aldosteronism: A Meta-analysis. The Journal of Clinical Endocrinology & Metabolism, 109(3), e1280-e1289. https://doi.org/10.1210/clinem/dgad654

Vancouver

Samnani S, Cenzer I, Kline GA, Lee SJ, Hundemer GL, McClurg C, et al. Time to Benefit of Surgery vs Targeted Medical Therapy for Patients With Primary Aldosteronism: A Meta-analysis. The Journal of Clinical Endocrinology & Metabolism. 2024;109(3):e1280-e1289. doi:10.1210/clinem/dgad654

BibTeX
@article{Samnani2024,
  author = {Samnani, Sunil and Cenzer, Irena and Kline, Gregory A and Lee, Sei J and Hundemer, Gregory L and McClurg, Caitlin and Pasieka, Janice L and Boscardin, W John and Ronksley, Paul E and Leung, Alexander A},
  title = {Time to Benefit of Surgery vs Targeted Medical Therapy for Patients With Primary Aldosteronism: A Meta-analysis},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  volume = {109},
  number = {3},
  pages = {e1280--e1289},
  doi = {10.1210/clinem/dgad654}
}
Kostenlos starten →